Senores Pharmaceuticals Ltd. (SPL) has entered into a Share Purchase Agreement (SPA) with a public shareholder of Havix Group Inc., doing business as Aavis Pharmaceuticals (Havix), to acquire 6,730 equity shares — representing 2.97 percent of Havix’s total paid-up share capital. The acquisition is subject to the terms and conditions outlined in the SPA.

Following this transaction, SPL’s aggregate shareholding in Havix — including that of its wholly owned subsidiary, Senores Pharmaceuticals Inc. (SPI), USA — will increase from 70.07 percent to 73.04 percent. This acquisition was approved by the company’s Management Committee of the Board of Directors during its meeting on July 10, 2025.

Havix is a US-based pharmaceutical company engaged in the development, manufacturing, and supply of various finished formulations.

Earlier in May, SPL, through its US subsidiary SPI, signed an agreement with Wockhardt to acquire the USFDA-approved Abbreviated New Drug Application (ANDA) for Enalapril Maleate Tablets (2.5mg, 5mg, 10mg, and 20mg). Enalapril is used to treat hypertension, heart failure, and asymptomatic left ventricular dysfunction.

Senores Pharmaceuticals is a global pharmaceutical company focused on the development and manufacturing of a broad range of products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms.

The company’s current portfolio includes 61 ANDAs and 22 CMO/CDMO commercial products authorised for distribution in the United States. 

Senores is also engaged in the development and manufacturing of complex generics certified by global food and drugs authorities and delivers generic drugs to more than 40 countries.

Its manufacturing site in Chhatral, Ahmedabad, India, is approved by regulatory agencies in over 10 countries, with more than 280 product registrations and 630 product applications.

 Senores also manufactures critical care injectables and Active Pharmaceutical Ingredients (API).

The company operates two formulation manufacturing facilities — one in Atlanta, USA and another in Chhatral, India. Additionally, it operates two API manufacturing facilities in India, located in Chhatral and Naroda, near Ahmedabad.